<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Metersky, Mark L.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Improving Outcomes of Ventilator-Associated Pneumonia</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">26-27</style></pages><abstract><style  face="normal" font="default" size="100%">Nosocomial pneumonia, especially ventilator-associated pneumonia (VAP), is a major cause of morbidity and mortality in the intensive care unit (ICU). This article discusses updates on bacterial resistance relevant to VAP, with a focus on methicillin-resistant Staphylococcus aureus (MRSA), treating MRSA pneumonia in the ICU, the use of tigecycline and doripenem for hospital-acquired pneumonia and VAP, and the potential utility of inhaled antibiotics as an alternative in the treatment of patients with VAP.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>